Showing 3381-3390 of 5689 results for "".
- Oxurion NV Reports Topline Phase 1 Results with THR-149 for the treatment of DMEhttps://modernod.com/news/oxurion-nv-reports-topline-phase-1-results-with-thr-149-for-the-treatment-of-dme/2476706/Oxurion NV reported positive topline data from a phase 1 study with THR-149, a novel, potent, plasma kallikrein (PKal) inhibitor for the treatment of diabetic macular edema (DME). THR-149 has been developed in partnership with Bicycle Therapeutics. Oxurion holds the exclusive license to the PKal
- New Research Suggests Glaucoma Screening Could Save Three Million Years Of Blindness In Chinahttps://modernod.com/news/new-research-suggests-glaucoma-screening-could-save-three-million-years-of-blindness-in-china/2476692/New research by Orbis International, Queen’s University Belfast, and Wenzhou Medical University has found that offering glaucoma screening in China could be highly cost-effective while reducing blindness among the population. The novel findings could change
- VSY Biotechnology is Now Accepting Applications for the “Ophthalmology Star Awards”https://modernod.com/news/vsy-biotechnology-is-now-accepting-applications-for-the-ophthalmology-star-awards/2476689/The Stars of Ophthalmology will be selected among the applicants who have a scientific article published in an ophthalmology journal since January 2018, according to a VSY Biotechnology news release. The articles are required to be authored in English and already published in order to be eligible
- A Single Course of Provention’s PRV-031 (Teplizumab) Delays Type 1 Diabetes Onset in High-Risk Individuals by at Least 2 Yearshttps://modernod.com/news/a-single-course-of-proventions-prv-031-teplizumab-delays-type-1-diabetes-onset-in-high-risk-individuals-by-at-least-2-years/2476644/Provention Bio announced that results from the National Institutes of Health (NIH)-sponsored “At-Risk” Study were published on-line in The New England Journal of Medicine and presented at the Scientific Sessions of the 79th Annual American Diabetes Association (ADA) meeting.
- SightLife Announces 100,000 Corneal Transplants in India Since Program Inception in 2009https://modernod.com/news/sightlife-announces-100000-corneal-transplants-in-india-since-program-inception-in-2009/2476639/SightLife announced that, together with its partners in India, 100,000 individuals suffering from corneal blindness have had their sight restored through a corneal transplant in the last 10 years since operations began in India. SightLife is a nonprofit global health organization dedicated to eli
- Verseon Showcases Oral Candidates for Next-Generation Diabetic Eye Disease Drugshttps://modernod.com/news/verseon-showcases-oral-candidates-for-next-generation-diabetic-eye-disease-drugs/2476626/Verseon presented a new class of oral candidate drugs which could change the treatment and prevention of diabetic macular edema (DME). “Our oral development candidate, a novel inhibitor of plasma kallikrein, has the potential to redefine how DME is treated,” Dr. Anirban Datta, Verse
- Oxurion Issues Financial and Business Updatehttps://modernod.com/news/oxurion-issues-financial-and-business-update/2476562/Oxurion NV issued a business and a financial update for the 3 months ending March 31, 2019. Oxurion is developing a competitive pipeline of disease modifying drug candidates for diabetic eye disease, particularly DME. The Oxurion clinical development pipeline consists of novel products wit
- Leiters Now Integrated into Besse Medical’s Inventory Management Systemshttps://modernod.com/news/leiters-now-integrated-into-besse-medicals-inventory-management-systems/2476547/Leiters and Besse Medical announced that they have entered into a national agreement to provide ophthalmic medications that are compatible with Besse Medical’s inventory management systems, CubixxMD and PODIS Plus. This new agreement enables Leiters’ full suite of ophthalmic medicatio
- Roche Further Extends Tender Offer for Spark Therapeutics as FTC Review Continueshttps://modernod.com/news/roche-further-extends-tender-offer-for-spark-therapeutics-as-ftc-review-continues/2476508/Roche said Friday that it is extending its offer period related to the proposed acquisition of Spark Therapeutics for a second time to give the US Federal Trade Commission (FTC) more time to review the deal, according to FirstWord. Roche noted that the FTC’s “review of the transaction
- Ophthotech Changes Name to Iveric bio as it Transitions to Gene Therapy Companyhttps://modernod.com/news/ophthotech-changes-name-to-iveric-bio-as-it-transitions-to-gene-therapy-company/2476473/Ophthotech announced that as part of its transition strategy to focus on discovering and developing novel gene therapy solutions to treat orphan inherited retinal diseases (IRDs) with unmet medical needs, the company